Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 142 No. 1920 (2012)

Use of abatacept in rheumatoid arthritis

  • Johannes von Kempis
  • Jean Dudler
  • Paul Hasler
  • Diego Kyburz
  • Alan Tyndall
  • Pascal Zufferey
  • Peter M. Villiger
DOI
https://doi.org/10.4414/smw.2012.13581
Cite this as:
Swiss Med Wkly. 2012;142:w13581
Published
06.05.2012

Summary

Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.

References

  1. Choy EH. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(3):510–8.
  2. Orencia® (Abatacept): Swiss prescribing information for physicians.
  3. Pettit AR, Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? Immunol Cell Biol. 1999;77(5):420–7.
  4. Janeway C. Immunobiology: The immune system in health and disease. 6th ed, New York: Garland Science Publishing. 2005:319–65; 557–612.
  5. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis. 2009;68(7):1220–7.
  6. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33(11):2162–6.
  7. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870–7.
  8. Westhovens R, Durez P, Genant H, Robles M, Becker JC, Covucci A, et al. Disease remission, normalized physical function and radiographic non-progression are achieved by the majority of patients with early rheumatoid arthritis treated with abatacept + methotrexate: results from the 2-year AGREE trial. Poster SAT0178, EULAR Annual Congress, June 16–19, 2010.
  9. Keystone E, Westhovens R, Moniz Reed D, Covucci A, Wells A. Radiographic progression correlates well with patient-reported RAPID3 disease activity levels in methotrexate (MTX).naive patients with early rheumatoid arthritis (RA): insights from the AGREE study. Arthritis & Rheumatism. 2010;62(10 Suppl):S470.
  10. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865–76.
  11. Dougados M, Kremer JM, Le Bars M, Reed D, Park S, Vatsanos G, et al. Abatacept improves disease activity status over time in patients with rheumatoid arthritis and an inadequate response to methotrexate [abstract]. Ann Rheum Dis. 2009;68:573.
  12. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096–103.
  13. Genant HK, Peterfy C, Westhovens R, Becker JC, Vratsanos G, Zhou X, et al. Abatacept increases the proportion of patients who remain free from structural damage progression through 5 years in methotrexate inadequate responders with rheumatoid arthritis. Poster FRI0253, EULAR Annual Congress, June 10–13, 2009.
  14. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114–23.
  15. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114–23.
  16. Schiff M, Keiserman MW, Moniz Reed D, Le Bars M, Becker J-C, Zhao C, et al. An increasing proportion of patients achieve a low disease activity state or remission when switched from infliximab to abatacept regardless of initial infliximab treatment response: results from the ATTEST trial. Poster 1659 (392), ACR/ARHP Annual Scientific Meeting, October 16–21, 2009.
  17. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708–14.
  18. Durez P, Bathon J, Becker JC, Covucci A, Moniz Reed D, Westhovens R. Time course of improvement in ACR core components in patients with early rheumatoid arthritis treated with abatacept plus methotrexate. Poster FRI0201, EULAR Annual Congress, June 16–19, 2010.
  19. Westhovens R, Moniz Reed D, Becker J-C, Vratsanos G, Yazici Y. Early improvements in disease activity with abatacept continue to increase or are maintained over time in methotrexate-naïve patients with early rheumatoid arthritis and poor prognostic factors. Poster SAT0109. EULAR Congress, 10–13 June, 2009.
  20. Westhovens R, Dougados M, Hall S, Moniz Reed D, Becker J-C, Teng J, et al. Disease remission, radiographic non-progression and normalization of function achieved at year 1 are sustained long-term in a majority of patients: 5-year outcomes with abatacept in biologic-naïve patients. Poster 1657 (390). ACR/ARHP Annual Scientific Meeting, October 16–21, 2009.
  21. Hochberg MH, Westhovens R, Aranda R, Kelly S, Khan N, Qi K, et al. Long-term safety of abatacept: integrated analysis of clinical program data of up to 7 years of treatment. Poster 390, ACR/ARHP Annual Scientific Meeting, November 7–11, 2010.
  22. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (Review). The Cochrane Library. 2011, Issue 2.
  23. Smitten A, Westhovens R, Hochberg M, Torbeyns A, Becker J-C, Aranda R. Serious infections and malignancies during long-term exposure to abatacept. Poster SAT0163, EULAR Annual Congress, June 16–19, 2010.
  24. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007;66:228–34.
  25. Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Research & Therapy. 2007;9:R38.
  26. Schiff M, Saewert M, Bahrt K, Genovese MC. Response to influenza vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Poster FRI 943/175, ACR Congress, November 6–11, 2007.
  27. Ribeiro A, Guedes L, Moraes J, Saad C, Calich A, Aikawa N, et al. Abatacept in association with traditional DMARDS severely impairs humoral response to pandemic A H1N1 influenza vaccination in rheumatoid arthritis patients. Ann Rheum Dis. 2011;70(Suppl3):458. Abstract FRI0342.
  28. Schiff M, Kaell A, Tay L, Vratsanos G, Bahrt K. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the ARRIVE trial. Poster SAT0029, EULAR, June 13–16, 2007.
  29. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Incidence of anti-nuclear and anti-DNA antibody seropositivity, and immunogenicity, in patients with rheumatoid arthritis treated with abatacept or infliximab. Poster SAT0030, EULAR, June 13–16, 2007.
  30. Jean Dudler, Burkhard Möller, Beat A. Michel, Peter M. Villiger. Biologics in rheumatoid arthritis (RA) – recommendations for Swiss practice. Swiss Med Wkly. 2011;141:w13189.

Most read articles by the same author(s)

<< < 1 2 3 > >>